Basit öğe kaydını göster

dc.contributor.authorBilgic, B
dc.contributor.authorHanagasi, Haşmet Ayhan
dc.contributor.authorSahin, HA
dc.contributor.authorEmre, M
dc.contributor.authorGurvit, IH
dc.date.accessioned2021-03-03T17:15:50Z
dc.date.available2021-03-03T17:15:50Z
dc.date.issued2002
dc.identifier.citationSahin H., Gurvit I., Bilgic B., Hanagasi H. A. , Emre M., "Therapeutic effects of an acetylcholinesterase inhibitor (Donepezil) on memory in Wernicke-Korsakoff's disease", CLINICAL NEUROPHARMACOLOGY, cilt.25, sa.1, ss.16-20, 2002
dc.identifier.issn0362-5664
dc.identifier.othervv_1032021
dc.identifier.otherav_48d440cb-3e1f-4a0c-b6de-e3ce3082237a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/52435
dc.description.abstractWernicke-Korsakoff's disease (WKD) is cognitively an amnestic state resulting from strategic lesions in the limbic system and resulting from thiamine deficiency. Neurochemical deficits have been implicated in the pathophysiology of amnesia based on the pathologic observations that various brainstem and basal forebrain nuclei are also affected. Previous treatment attempts with serotoninergic, noradrenergic, and cholinergic drug, hake given controversial results, The objective of this study was to assess the effects of a cholinesterase inhibitor, donepezil. on memory. attention, and executive C functions in patients with nonalcoholic WKD. Seven patients who developed WKD after a hunger strike were included in this single. blind, placebo-controlled. one-ay, crossover study. The patients were administered donepezil during the first 30 days, and were administered placebo during the 1,following 30 days. Neuropsychological tests to evaluate herbal and visual memory, and attention and executive function were performed on days 0, 3 1, and 6 1, All patients completed both phases of the study. There were no statistically significant differences between the three evaluations, except For a difference between active treatment and the placebo phase during recall of the Rey-Osterrieth complex figure, which as in favor of the placebo phase. There were no significant changes in favor of the active treatment. Cholinergic treatment with the cholinesterase inhibitor donepezil doe,,, not seem to provide marked beneficial effects in patients with WKD in this small. descriptive Study. This may be because pathways mediating channel and state-dependent functions are impaired in this disease, and enhancement of state-dependent cholinergic transmission may not be sufficient, Subtle benefits, however, cannot be excluded because of the small sample size and the relatively short duration of the treatment.
dc.language.isoeng
dc.subjectEczacılık
dc.subjectKLİNİK NEUROLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.titleTherapeutic effects of an acetylcholinesterase inhibitor (Donepezil) on memory in Wernicke-Korsakoff's disease
dc.typeMakale
dc.relation.journalCLINICAL NEUROPHARMACOLOGY
dc.contributor.department, ,
dc.identifier.volume25
dc.identifier.issue1
dc.identifier.startpage16
dc.identifier.endpage20
dc.contributor.firstauthorID163806


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster